Climb Bio Details CD19 and APRIL 2025 Data Catalysts at Oppenheimer Conference
Climb Bio outlined data catalysts for 2025 in its CD19 B-cell malignancy immunotherapy and APRIL multiple myeloma program, presenting at the Oppenheimer conference on February 26, 2026. The company highlighted expected clinical readouts and regulatory milestones that could influence its late-stage pipeline valuation.
1. Conference Highlights
At the Oppenheimer conference on February 26, 2026, Climb Bio underscored its 2025 data catalysts for the CD19 immunotherapy targeting B-cell malignancies and the APRIL-focused multiple myeloma program, noting anticipated clinical readouts and regulatory filings that could unlock value in its late-stage pipeline.
Related News
GOOG
Google, Blackstone Launch $5B AI Cloud JV with 500MW Capacity by 2027
GOOG•
INTC
Nvidia’s $91B AI Forecast, $80B Buyback Ramps Up Pressure on Intel
INTC•
EQNR
Equinor Sells 19% Ringvei Vest Stakes, Increases Wisting to 42.5% for $23M
EQNR•
MWC
Micware Co. Soars 51.5% in IPO Debut, Raises $22.8M
MWC•
UPS
UPS MD-11 Crash After Engine Mount Inspections Extended to 29,260 Cycles
UPS•
Sources
F